Medical Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, 47003, Spain.
Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 28922, Spain.
Per Med. 2022 Jul;19(4):341-359. doi: 10.2217/pme-2021-0059. Epub 2022 Jun 24.
In recent years, major advances have been achieved in our understanding of non-small-cell lung cancer (NSCLC) with oncogenic driver alterations and in the specific treatment of these with tyrosine kinase inhibitors. Currently, state-of-the-art management of patients with NSCLC (particularly adenocarcinoma or non-adenocarcinoma but with mild tobacco exposure) consists of the determination of , , and status, as they have US FDA and EMA approved targeted therapies. The increase in molecular knowledge of NSCLC and the development of drugs against other targets has settled new therapeutic indications. In this review we have incorporated the development around MET, KRAS and NTRK in the diagnosis of NSCLC given the therapeutic potential that they represent, as well as the drugs approved for these indications.
近年来，我们对致癌驱动因素改变的非小细胞肺癌（NSCLC）有了更深入的了解，并在针对这些因素的酪氨酸激酶抑制剂的特定治疗方面取得了重大进展。目前，NSCLC（特别是腺癌或非腺癌但有轻度吸烟史）患者的先进治疗方法包括检测 、 、 和 状态，因为这些方法都有美国食品药品监督管理局和欧洲药品管理局批准的靶向治疗药物。NSCLC 分子知识的增加和针对其他靶点药物的开发为新的治疗适应症奠定了基础。在本综述中，我们考虑了 MET、KRAS 和 NTRK 检测在 NSCLC 诊断中的发展，因为它们具有治疗潜力，并且已经批准了这些适应症的药物。
